1. Home
  2. DNUT vs MNPR Comparison

DNUT vs MNPR Comparison

Compare DNUT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.24

Market Cap

598.2M

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$109.90

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
MNPR
Founded
1937
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
598.2M
587.4M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
DNUT
MNPR
Price
$3.24
$109.90
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$4.15
$107.00
AVG Volume (30 Days)
2.7M
208.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.99
EPS
N/A
N/A
Revenue
$1,522,616,000.00
N/A
Revenue This Year
$0.55
N/A
Revenue Next Year
$3.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.88
$29.18
52 Week High
$5.11
$116.64

Technical Indicators

Market Signals
Indicator
DNUT
MNPR
Relative Strength Index (RSI) 41.48 64.85
Support Level $3.18 $52.92
Resistance Level $3.74 $112.57
Average True Range (ATR) 0.12 8.44
MACD -0.02 -0.78
Stochastic Oscillator 27.27 77.58

Price Performance

Historical Comparison
DNUT
MNPR

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: